A phase 3 study of ISIS-TTRrx in TTR-related cardiomyopathy patients

Trial Profile

A phase 3 study of ISIS-TTRrx in TTR-related cardiomyopathy patients

Suspended
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2016

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloidosis; Cardiomyopathies
  • Focus Registrational; Therapeutic Use
  • Acronyms CARDIO-TTR
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Apr 2016 According to an Ionis Pharmaceuticals media release, the US FDA has placed a clinical hold on the CARDIO-TTR study while GSK provides answers to questions about the protocol stemming from Ionis' ongoing NEURO-TTR study.
    • 03 Nov 2015 Study design presented at the First European Congress on Hereditary ATTR amyloidosis 2015, according to an Isis Pharmaceuticals media release.
    • 24 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top